Table 3.
Direct and indirect evidences and network meta‐analysis results summary table for PASI 90 at 12 to 16 weeks
| Network meta‐analysis | Direct evidence | Indirect evidence | |||||||
| Comparisons* | RR | LCI | UCI | RR | LCI | UCI | RR | LCI | UCI |
| FAEs vs placebo | 4.09 | 1.88 | 8.88 | 4.47 | 1.97 | 10.14 | 1.86 | 0.16 | 21.16 |
| Methotrexate vs placebo | 3.91 | 2.16 | 7.08 | 1.53 | 0.66 | 3.53 | 17.16 | 5.69 | 51.75 |
| Adalimumab vs placebo | 14.87 | 10.45 | 21.14 | 14.42 | 10.08 | 20.64 | 108.8 | 2.24 | 5287.86 |
| Etanercept vs placebo | 10.79 | 8.47 | 13.73 | 10.62 | 7.52 | 15.01 | 11.21 | 7.26 | 17.32 |
| Ustekinumab vs placebo | 19.91 | 15.11 | 26.23 | 22.7 | 15.46 | 33.34 | 17.91 | 12.71 | 25.24 |
| Secukinumab vs placebo | 26.55 | 20.32 | 34.69 | 24.53 | 14.93 | 40.32 | 28.25 | 19.1 | 41.78 |
| Ixekizumab vs placebo | 32.45 | 23.61 | 44.60 | 39.46 | 20.64 | 75.44 | 24.51 | 10.05 | 59.77 |
| Brodalumab vs placebo | 25.45 | 18.74 | 34.57 | 26.58 | 16.65 | 42.41 | 23.74 | 10.09 | 55.86 |
| Apremilast vs placebo | 7.66 | 4.30 | 13.66 | 6.72 | 3.07 | 14.69 | 10.83 | 2.43 | 48.31 |
| Tofacitinib vs placebo | 8.50 | 6.23 | 11.60 | 6.3 | 4.14 | 9.56 | 17.91 | 8.3 | 38.62 |
| Guselkumab vs placebo | 21.03 | 14.56 | 30.38 | 26.1 | 14.71 | 46.3 | 12.7 | 4.28 | 37.69 |
| Methotrexate vs FAEs | 0.96 | 0.38 | 2.44 | 2 | 0.19 | 21.03 | 0.83 | 0.3 | 2.32 |
| Alefacept vs methotrexate | 1.12 | 0.42 | 3.02 | 1.12 | 0.42 | 3.02 | |||
| Ciclosporin vs methotrexate | 1.02 | 0.60 | 1.73 | 1.02 | 0.6 | 1.73 | |||
| Infliximab vs methotrexate | 2.86 | 2.06 | 3.97 | 2.86 | 2.06 | 3.97 | |||
| Adalimumab vs methotrexate | 3.80 | 2.26 | 6.39 | 3.35 | 2.02 | 5.57 | 13.2 | 3.4 | 51.32 |
| Etanercept vs acitretin | 11.00 | 0.63 | 191.47 | 11 | 0.63 | 191.47 | |||
| Guselkumab vs adalimumab | 1.41 | 1.21 | 1.65 | 1.4 | 1.18 | 1.66 | 2.88 | 0.68 | 12.21 |
| Ustekinumab vs etanercept | 1.85 | 1.50 | 2.27 | 1.8 | 1.27 | 2.55 | 1.95 | 1.37 | 2.77 |
| Secukinumab vs etanercept | 2.46 | 2.01 | 3.02 | 2.33 | 1.66 | 3.28 | 2.62 | 1.82 | 3.77 |
| Ixekizumab vs etanercept | 3.01 | 2.46 | 3.68 | 2.93 | 2.44 | 3.53 | 5.73 | 2.07 | 15.85 |
| Apremilast vs etanercept | 0.71 | 0.40 | 1.25 | 0.72 | 0.36 | 1.45 | 0.69 | 0.26 | 1.81 |
| Tofacitinib vs etanercept | 0.79 | 0.59 | 1.06 | 0.88 | 0.73 | 1.08 | 0.49 | 0.3 | 0.81 |
| Secukinumab vs ustekinumab | 1.33 | 1.11 | 1.61 | 1.38 | 1.03 | 1.84 | 1.19 | 0.79 | 1.81 |
| Brodalumab vs ustekinumab | 1.28 | 1.10 | 1.48 | 1.27 | 1.1 | 1.46 | 1.64 | 0.69 | 3.89 |
FAES: fumaric acid esters; LCI: low confidence interval; RR: risk ratio; UCI: upper confidence interval; vs: versus,
*The comparisons listed in this table were included in at least one direct‐evidence analysis.